🇺🇸 FDA
Pipeline program

MAT2203

MB-70007

Phase 3 small_molecule active

Quick answer

MAT2203 for Cryptococcal Meningitis is a Phase 3 program (small_molecule) at Matinas BioPharma Holdings with 2 ClinicalTrials.gov record(s).

Program details

Company
Matinas BioPharma Holdings
Indication
Cryptococcal Meningitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials